Updates are available Correction dated 2023-03-13
Click to view Correction: https://doi.org/10.1038/s41565-023-01345-y
Updates are available Correction dated 2023-08-10
Click to view Correction: https://doi.org/10.1038/s41565-023-01499-9
-
Authors
Detappe, Alexandre
Nguyen, Hung V.-T.
Jiang, Yivan
Agius, Michael P.
Wang, Wencong http://orcid.org/0000-0001-9578-209X
Mathieu, Clelia
Su, Nang K.
Kristufek, Samantha L.
Lundberg, David J.
Bhagchandani, Sachin
Ghobrial, Irene M. http://orcid.org/0000-0001-7361-3092
Ghoroghchian, P. Peter
Johnson, Jeremiah A. http://orcid.org/0000-0001-9157-6491
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA220468-01)
- License Information
-
More Information
Article History
Received: 26 February 2021
Accepted: 6 December 2022
First Online: 26 January 2023
Change Date: 13 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41565-023-01345-y
Change Date: 10 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41565-023-01499-9
Competing interests
: A.D., H.V.-T.N., Y.J., I.M.G., P.P.G. and J.A.J. are named inventors on a patent application (US patent application no. 16/825,269) jointly filed by the Massachusetts Institute of Technology and the Dana-Farber Cancer Institute on the Btz macromolecular PIs described in this work. H.V.-T.N., Y.J. and J.A.J. are co-founders and shareholders of Window Therapeutics, which seeks to translate this technology to clinical cancer therapies. The other authors declare no competing interests.
